Poltreg SA is a Poland-based company engaged primarily in biotechnology and medical research. The Company conducts research in the field of autoimmunological diseases. The Company works on a method of healing, that uses t-regulated cells (TREGs). The Firm possesses its own, patented technology to obtain T-regulated lymphocytes, that are used in the therapy. The Company works on therapy for diseases such as type one diabetes, type two diabetes, and multiple sclerosis. In its research, the Company cooperates with multiple specialists from various fields of science. The Company is developing its own research center, which is intended as a basic location for conducting future research activities.

Employees

Sector

Biotechnology & Medical Research

Calendar

09-08 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-07-24	PLN 23.40	+1.74%	1,767
26-07-23	PLN 23.00	0.00%	5,681
26-07-22	PLN 23.00	-2.13%	4,984
26-07-21	PLN 23.50	-2.89%	26,509
26-07-20	PLN 24.20	+23.47%	22,440

Delayed Quote Warsaw S.E.

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Delayed Warsaw S.E. Other stock markets 06:31:08 2026-07-24 EDT			5-day change	1st Jan Change
23.40 ^PLN	+1.74%		+19.39%	-4.49%

05-11	Poltreg S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-05	Poltreg S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	136M 35.71M 31.4M 29.17M 26.83M 50.32M 3.46B 51.22M 349M 1.69B 134M 131M 5.85B	P/E 2026 *	-4.38x	P/E 2027 *	6.01x
Enterprise Value	127M 33.42M 29.4M 27.31M 25.12M 47.1M 3.24B 47.95M 327M 1.58B 125M 123M 5.48B	EV / Sales 2026 *	106x	EV / Sales 2027 *	0.93x
Free-Float	72.15%	Yield 2026 *	-	Yield 2027 *	-

05-11	Poltreg S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-05	Poltreg S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-10	PolTREG SA Moves Forward With European Registration Process For TREG Therapy In Type 1 Diabetes	CI
11-19	Poltreg S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-07	Immuthera and Its Wholly Owned Subsidiary of Poltreg S.A Appoints Adrian Bot to Its Board of Directors	CI
25-09-10	Poltreg S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-08-04	PolTREG S.A. Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007	CI
25-07-31	Poltreg and Immuthera Secure Positive FDA Opinion, Paving the Way for a Registrational Pre-Symptomatic Type 1 Diabetes Trial	CI
25-06-13	Poltreg Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy	CI
25-06-13	Poltreg Establishes U.S. Subsidiary Immuthera To Advance International Development Strategy	RE
25-05-15	PolTREG S.A. Announces Positive Ema Opinion on Pediatric Investigation Plan for PolTREG's Treg Therapy in Type 1 Diabetes	CI
25-05-14	Poltreg S.A. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-16	Poltreg S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

03-10	PolTREG moves forward with the European registration process for TREG therapy in type 1 diabetes	GL
11-07	Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapies	GL
25-08-04	PolTREG Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007	GL
25-07-31	PolTREG and U.S. Subsidiary Immuthera Secure Positive FDA Opinion, Paving the Way for a Registrational Pre-Symptomatic Type 1 Diabetes Trial	GL
25-07-04	Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions	GL

Poltreg S.A. Stock

Stocks

PTG

PLPLTRG00038

Biotechnology & Medical Research

Valuation: Poltreg S.A.

Chart: Poltreg S.A.

Latest news : Poltreg S.A.

Press Releases: Poltreg S.A.

News in other languages: Poltreg S.A.

Quotes and Performance

Course Extremes

Managers and Directors: Poltreg S.A.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

03-11	PolTREG poursuit la procédure d’enregistrement au niveau européen de sa thérapie à base de TREG destinée au traitement du diabète de type 1
03-11	PolTREG treibt das europäische Zulassungsverfahren für die TREG-Therapie bei Typ-1-Diabetes voran

1 day	+1.74%
1 week	+19.39%
Current month	+25.13%
1 month	+24.80%
3 months	+36.05%
6 months	-8.95%
Current year	-4.49%

1 week	19.5	25
1 month	17.55	25
Current year	16	28.6
1 year	16	36
3 years	16	65
5 years	16	73.9
10 years	16	73.9

Manager	Title	Age	Since
Piotr Trzonkowski CEO	Chief Executive Officer	-	2019-04-30
Marta Druch CTO	Chief Tech/Sci/R&D Officer	-	2021-10-31
Daniel Shelly PRN	Corporate Officer/Principal	-	2024-02-20

Director	Title	Age	Since
Oktawian Zbigniew Jaworek BRD	Director/Board Member	50	2021-05-20
Michal Dariusz Wnorowski BRD	Director/Board Member	53	-
Marcin Jerzy Mierzwiñski CHM	Chairman	-	2021-05-23

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
POLTREG S.A.	+1.74%	+19.39%	-25.71%	-59.66%	35.71M
LONZA GROUP AG	+1.44%	-3.42%	-3.18%	+12.96%	46.35B
REVOLUTION MEDICINES, INC.	+3.13%	+5.34%	+402.93%	+605.08%	40.13B
BEONE MEDICINES AG	+2.14%	+2.95%	+10.83%	+65.45%	36.33B
IQVIA HOLDINGS INC.	+4.43%	-1.51%	+6.73%	-9.17%	34.6B
CELLTRION, INC.	+1.23%	-2.05%	+0.56%	+30.76%	26.77B
ASCENDIS PHARMA A/S	+0.29%	-2.75%	-	-	16.66B
MEDPACE HOLDINGS, INC.	+14.71%	+12.62%	+38.50%	+146.99%	16.91B
EUROFINS SCIENTIFIC SE	+0.64%	-5.32%	+0.97%	+8.73%	13.05B
ICON PUBLIC LIMITED COMPANY	+1.82%	+0.19%	+1.45%	-30.74%	13.05B
Average	+3.05%	+2.09%	+48.12%	+85.60%	24.39B
Weighted average by Cap.	+2.88%	+0.23%	+76.33%	+131.86%

	2026 *	2027 *
Net sales	1.2M 315K 277K 257K 237K 444K 30.49M 452K 3.08M 14.87M 1.18M 1.16M 51.6M	116M 30.54M 26.86M 24.96M 22.95M 43.04M 2.96B 43.82M 298M 1.44B 115M 112M 5.01B
Net income	-29.4M -7.71M -6.79M -6.3M -5.8M -10.87M -747M -11.07M -75.37M -364M -28.96M -28.34M -1.26B	24.2M 6.35M 5.59M 5.19M 4.77M 8.95M 615M 9.11M 62.04M 300M 23.84M 23.32M 1.04B
Net Debt	-8.7M -2.28M -2.01M -1.87M -1.72M -3.22M -221M -3.27M -22.3M -108M -8.57M -8.39M -374M	-28.4M -7.45M -6.55M -6.09M -5.6M -10.5M -722M -10.69M -72.81M -352M -27.98M -27.37M -1.22B